AUTHORS
Irina Pivneva, PhD, Sakshi Sethi2, Elyse Swallow, BA, MA3, Jorge Caicedo, MD4, Maureen Watt, MSc5
AFFILIATIONS
1 Analysis Group, Inc., Montreal, Quebec, Canada
2 Analysis Group, Inc., New York, New York, United States
3 Analysis Group, Inc., Boston, Massachusetts, United States
4 Takeda Pharmaceuticals U.S.A, Inc., Lexington, Massachusetts, United States
5 Takeda Development Center Americas, Inc., Cambridge, Massachusetts, United States
ABSTRACT
Introduction
Von Willebrand disease (VWD) is a congenital bleeding disorder characterized by qualitative or quantitative defects in von Willebrand factor (VWF). Treatment options for bleeding events in patients with VWD include plasma-derived (pdVWF) or recombinant VWF (rVWF) concentrates with or without factor VIII (FVIII). In the United States, rVWF (VONVENDI®; Takeda Pharmaceuticals USA, Inc., Lexington, MA, USA) is approved in adult and pediatric patients with VWD for the on-demand treatment of bleeding episodes and the management of perioperative bleeding, and in adults for routine prophylaxis to reduce bleeding frequency. Information on routine rVWF prophylaxis in clinical practice remains limited, particularly for Type 1 and Type 2 VWD. Here, we describe the real-world demographic and clinical characteristics, treatment patterns, clinical outcomes, and healthcare resource utilization (HCRU) of patients with Type 1 and Type 2 VWD in the United States receiving routine rVWF prophylaxis.
Methods
This retrospective, non-interventional chart review used medical record data extracted by physicians. Eligible patients had a confirmed diagnosis of Type 1 or Type 2 VWD, had initiated routine rVWF prophylaxis for the first time, and were aged ≥6 years. The index date was the date of initiation of routine rVWF prophylaxis, defined as rVWF administration at least twice weekly for at least three consecutive months. Data on patient demographics, clinical characteristics, treatment patterns, clinical outcomes, and HCRU were collected using an electronic case report form. Clinical outcomes were assessed during the 12-month pre-index period and from index to treatment discontinuation, end of data availability, or death, whichever occurred first. Annualized bleeding rate (ABR) was calculated as the number of bleeding events divided by the duration of the pre- or post-index period (months) and multiplied by 12. HCRU outcomes, including VWD-specific hospitalizations, emergency room (ER) visits, and outpatient (OP) visits, were assessed during the 12-month pre-index period and from index to the earliest of 12 months post-index, end of data availability, or death. Results are summarized for the overall population, with selected outcomes also presented by VWD type.
Results
In total, 26 physicians extracted data from the medical records of 91 patients with VWD (Type 1, n=39 [42.9%]; Type 2, n=52 [57.1%]). Median (interquartile range [IQR]) age at initiation of rVWF prophylaxis was 21.4 (16.4, 32.1) years. The most common comorbidities were anemia (n=29 [31.9%]) and iron deficiency (n=28 [30.8%]).
Twelve (13.2%) patients received prophylactic VWD treatment prior to rVWF prophylaxis initiation, including pdVWF/FVIII concentrates (n=3 [3.3%]). Median (IQR) duration of rVWF prophylaxis was 13.6 (6.2, 26.1) months. The most common reasons for initiating rVWF prophylaxis were effectiveness (n=72 [79.1%]), patient preference (n=33 [36.3%]), and caregiver preference (n=32 [35.2%]).
The mean (SD) ABR for all bleeding events decreased from 1.7 (2.9) during the 12-month pre-index period to 0.2 (0.4) during the post-index period (median duration: 13.5 months). Similar reductions were observed among patients with Type 1 and Type 2 VWD (Type 1: pre-index, 1.9 [2.8]; post-index, 0.2 [0.4]; Type 2: pre-index, 1.6 [2.9]; post-index, 0.1 [0.3]).
The number of patients with at least one hospitalization decreased from 12 (13.2%) pre-index to 2 (2.2%) post-index; ER visits also decreased from 26 (28.6%) pre-index to 12 (13.2%) post-index, while OP visits were stable (pre-index, n=72 [79.1%]; post-index, n=74 [81.3%]). Similar trends were noted among patients with Type 1 and Type 2 VWD, with the number of patients who experienced at least one hospitalization or ER visit decreasing from pre- to post-index (hospitalization: Type 1, n=3 [7.7%] to n=1 [2.6%]; Type 2, n=9 [17.3%] to n=1 [1.9%]; ER visit: Type 1, n=8 [20.5%] to n=3 [7.7%]; Type 2, n=18 [34.6%] to n=9 [17.3%]). The number of patients with at least one OP visit was similar in the pre- and post-index periods (Type 1, n=33 [84.6%] to n=36 [92.3%]; Type 2, n=39 [75.0%] to n=38 [73.1%]).
Conclusions
This descriptive real-world study showed improvements in clinical outcomes and reductions in HCRU following routine rVWF prophylaxis among patients with Type 1 and Type 2 VWD in the United States. These findings add to the growing body of evidence supporting the use of rVWF prophylaxis in routine clinical practice.
DISCLOSURES
Jorge Caicedo, MD: Takeda Pharmaceuticals U.S.A, Inc. - Current equity holder in publicly-traded company; Employee of Takeda Pharmaceuticals U.S.A., Inc. and stockholder of Takeda - Current holder of stock options in a privately-held company; Employee of Takeda Pharmaceuticals U.S.A., Inc. and stockholder of Takeda - Current Employment; Takeda Pharmaceuticals U.S.A, Inc. - Current Employment